Author: Customer Service

PRINCETON, NEW JERSEY, July 30, 2026 (GLOBE NEWSWIRE) — Digital Asset Acquisition Corp. (Nasdaq: DAAQ) (the “Company”) announced that its upcoming extraordinary general meeting of shareholders (the “Meeting”) to approve its proposed initial business combination, which was initially scheduled for July 31, 2026, will be postponed to 10:00 a.m., Eastern Time on August 14, 2026. At the Meeting, shareholders of DAAQ will be asked to vote on proposals to approve, among other things, DAAQ’s proposed initial business combination (the “Business Combination”) with Old Glory Holding Company (“Old Glory Bank”), a Delaware corporation. As a result of this change, the Meeting will now be held at 10:00 a.m., Eastern time, on August 14, 2026, at the office of Ashurst Perkins Coie US LLP located at 1155 Avenue of the Americas, New York, New York...

SYDNEY, July 30, 2026 (GLOBE NEWSWIRE) — Omni Bridgeway Limited (ASX: OBL), a leading global alternative asset manager specialising in legal assets, has released its Investment Portfolio Report as at 30 June 2026. FY26 delivered record new commitments and record cash investment proceeds, alongside strong completion metrics, disciplined cost management and continued growth in fee income, reflecting the scale and diversification of the Group’s global legal assets platform. Key HighlightsRecord new commitments: FY26 new conditional and unconditional commitments reached A$712.2 million across 43 new investments, a record for the Group and approximately 38% above FY25. A$343.0 million was committed in the June quarter alone, as the exceptional pipeline reported at 3Q26 converted into contracted investments. Record investment...

CALGARY, Alberta, July 30, 2026 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company”) announces that it intends to consolidate the common shares of the Company (“Common Shares”) on a ten-to-one basis (the “Consolidation”). The Company has 59,158,004 Common Shares outstanding and, if completed, the proposed Consolidation would reduce the issued and outstanding Common Shares to approximately 5,915,800 Common Shares. The Company will issue a subsequent news release, following its filing of all necessary documentation with the Canadian Securities Exchange (“CSE”) in respect of the proposed Consolidation, announcing the effective date of the proposed Consolidation, the new CUSIP and ISIN for the consolidated Common Shares and any other relevant details regarding the proposed Consolidation. No fractional...

Smart novated leasing now available in Hyundai and Genesis dealershipsSX2 KONA Electric N Line, just one of the vehicles available through a novated lease and Hyundai or Genesis dealerships in Australia.SYDNEY, July 30, 2026 (GLOBE NEWSWIRE) — Australia’s leading salary packaging and novated leasing provider, Smart, has partnered with Hyundai Capital Australia to make the savings of novated leasing easier, more accessible, and more convenient for customers through Hyundai and Genesis dealerships. Under the partnership, Hyundai and Genesis dealerships will introduce eligible customers to Smart for novated leasing and salary packaging services, creating a more seamless path for customers to explore their options at the point of vehicle purchase. A key advantage of novated leasing is the fully maintained lease, which bundles...

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) — Churchill Capital Corp XIII (the “Company”) announced the pricing of its upsized initial public offering of 36,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “XIIIU” commencing today. Each unit consists of one Class A ordinary share of the Company and one-tenth of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Company expects that the Class A ordinary shares and warrants will be listed on Nasdaq under the symbols “XIII” and “XIIIW,” respectively. The offering is expected to close on August 3, 2026, subject to customary closing conditions.  Churchill...

Hong Kong, July 30, 2026 (GLOBE NEWSWIRE) — INNO HOLDINGS INC. (Nasdaq: INHD) (“INNO” or the “Company”), a Texas holding company, today announced that its common stock will resume trading on The Nasdaq Capital Market. As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 12, 2026, The Nasdaq Stock Market LLC imposed a trading halt under Code T12 on the trading of the Company’s common stock. The trading halt is being lifted and, as a result, trading of the Company’s common stock is expected to resume on The Nasdaq Capital Market at or around noon, eastern time on July 31, 2026, rather than at the opening of trading as previously announced. The Company is not aware of any material, undisclosed corporate developments that would account for the unusual trading activities...

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call will be held at 9:00 a.m. AEST on Thursday August 20, 2026 (7:00 p.m. EDT Wednesday August 19, 2026). Participants can register for the webcast or teleconference at the following link: https://s1.c-conf.com/diamondpass/10056417-pz2402.html About Telix Pharmaceuticals Limited Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted...

Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today’s meeting of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), which discussed the Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy. The committee discussed two topics: (1) whether the single-arm IGNYTE study, as designed and conducted, allows for a reliable...